Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo

Adv Mater. 2020 Oct;32(40):e2004452. doi: 10.1002/adma.202004452. Epub 2020 Sep 2.

Abstract

SARS-CoV-2 has become a pandemic worldwide; therefore, an effective vaccine is urgently needed. Recently, messenger RNAs (mRNAs) have emerged as a promising platform for vaccination. In this work, the untranslated regions (UTRs) of mRNAs are systematically engineered in order to enhance protein production. Through a comprehensive analysis of endogenous gene expression and de novo design of UTRs, the optimal combination of 5' and 3' UTR are identified and termed NASAR, which are 5- to 10-fold more efficient than the tested endogenous UTRs. More importantly, NASAR mRNAs delivered by lipid-derived TT3 nanoparticles trigger a dramatic expression of potential SARS-CoV-2 antigens. The antigen-specific antibodies induced by TT3-nanoparticles and NASAR mRNAs are over two orders of magnitude more than that induced by the FDA-approved lipid nanoparticle material MC3 in vaccinated mice. These NASAR mRNAs merit further development as alternative SARS-CoV-2 vaccines.

Keywords: SARS-CoV-2; lipid-derived nanoparticles; mRNA engineering; mRNA vaccines; untranslated regions.

MeSH terms

  • Animals
  • Antibodies, Viral / metabolism
  • Antigens, Viral / administration & dosage*
  • Betacoronavirus / immunology*
  • COVID-19 Vaccines
  • Cell Line, Tumor
  • Coronavirus Infections / prevention & control
  • Female
  • Gene Expression
  • HEK293 Cells
  • Humans
  • Mice, Inbred C57BL
  • Nanoparticles
  • RNA, Messenger
  • SARS-CoV-2
  • Vaccination
  • Viral Vaccines*

Substances

  • Antibodies, Viral
  • Antigens, Viral
  • COVID-19 Vaccines
  • RNA, Messenger
  • Viral Vaccines